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logical parameters. Primary cells obtained from OC patient 
samples were applied in fluorescence microscopy analysis for 
examination of PAI-1 and PAI-RBP1 distribution. Results: PAI-
1 and PAI-RBP1 have been found to be predictive markers for 
OC patients’ outcome. PAI-1 levels significantly correlated 
with volume of ascites, FIGO staging, and lymph node status. 
PAI-RBP1 expression significantly correlated with age at first 
diagnosis, histological tumor type, presence of distant me-
tastasis (pM), and recurrence. PAI-1 showed a trend toward 
association and PAI-RBP1 was significantly associated with 
progression-free survival. Notably, PAI-1 protein in recurrent 
OC tissues was exclusively localized in the nucleus. Conclu-
sion: This study has shown that a combination of PAI-1 and 
PAI-RBP1 may represent novel prognostic factor for OC. Pro-
spective trials are needed. © 2017 S. Karger AG, Basel
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Abstract
Background: The plasminogen activator system plays a key 
role in ovarian cancer (OC) tumor progression. The plasmino-
gen activator inhibitor type 1 (PAI-1) and the recently identi-
fied PAI-1 RNA binding protein 1 (PAI-RBP1) are primary reg-
ulators of plasminogen activation and thus are putative bio-
markers for OC progression. Methods: One hundred fifty six 
OC patients were analyzed to identify the presence of PAI-1 
and PAI-RBP1 and subsequently correlated to clinicopatho-
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Introduction
Although ovarian cancer (OC) ranks eighth among the 
most common female malignancies, it is the fifth cause of 
death due to cancer in women [1]. This discrepancy is 
largely attributed to the fact that the majority of patients 
present with advanced disease at the time of diagnosis. 
Furthermore, only one molecular marker exists for OC 
therapy. Patients with mutations of breast cancer types 1 
and 2 susceptibility protein (BRCA1/2) genes most likely 
benefit from olaparib treatment [2]. Therefore, the iden-
tification of novel molecular biomarkers could potential-
ly lead to improvement in prognosis and development of 
novel therapeutic approaches using targeted therapy.
In solid tumors, motility and invasiveness of cancer 
cells require the activation of proteolytic enzymes leading 
to the degradation of the extracellular matrix and base-
ment membrane. The urokinase plasminogen activator 
(uPA) system plays a key role in tumor cell invasion and 
metastasis. Plasminogen activator inhibitor type 1  (PAI-1) 
is the primary regulator of plasminogen activation and a 
member of the serpin superfamily. PAI-1 plays crucial 
roles in promoting tumor progression by regulating cell 
motility, extracellular matrix remodelling, and intracel-
lular signaling pathways [3]. Consequently, elevated 
 PAI-1 levels have been detected in numerous carcinomas 
[4, 5]. Moreover, a relationship between uPA and PAI-1 
and clinical prognostic factors in primary breast can-
cer has been demonstrated and the clinical utility of uPA/
PAI-1 as a dual-biomarker concept has been confirmed 
in level-of-evidence-1 studies [6, 7].
Performing a computational expressed sequence tag 
database analysis, we previously identified the PAI-1 
RNA-binding protein 1 (PAI-RBP1) being upregulated in 
OC cells and verified this finding by in situ hybridization 
and immunohistochemistry in OC tissue samples [8]. As 
PAI-RBP1 exerts PAI-1 mRNA-binding capacity, it is 
most likely that PAI-RBP1 modulates mRNA translation 
by affecting the mRNA turn-over or the translational 
complex functionality [9]. Some data provide evidence 
that PAI-RBP1 activity is regulated by cyclic nucleotides 
and by the subcellular localization of the protein. In this 
study, we analyzed intracellular protein levels and subcel-
lular protein localization of PAI-1 and PAI-RBP1 in pri-
mary and recurrent OC tissue samples. Subsequently, 
protein alterations were statistically correlated to clinical 
parameter. The aim of this study was to evaluate the use-
fulness of PAI-1 and PAI-RBP1 expression and cellular 
distribution as prognostic biomarkers, particularly in the 
concept of a PAI-1/PAI-RBP1 dual-biomarker strategy.
Methods
Patients
This study was conducted within the framework of the Tumor-
bank Ovarian Cancer Network (http://www.toc-network.de) and 
has been approved by the Ethics Committees of the participating 
centers (University Medicine Greifswald, Germany; Charité Med-
ical University Berlin, Germany; Medical Center University of 
Freiburg, Germany; Clinic Bayreuth, Germany; Oncological Insti-
tute Chisinau, Moldova). All patients signed informed consent 
forms. For the study, patients with primary and recurrent OC were 
included. The majority of patients with primary OC underwent 
radical surgery. Surgical treatment in patients with recurrent OC 
involved maximal tumor debulking.
Data Collection
All clinical data, including age, FIGO stage, prior surgical pro-
cedures, all surgical procedures, postoperative residual tumor and 
histopathological diagnosis were collected with the help of a stan-
dardized systematic documentation tool (IMO) [10]. The attend-
ing physician performed standard follow-up visits according to the 
established protocols, that is, every 3 months during standard fol-
low-up examinations or by checking the regional tumor registry or 
by telephone interview all clinical data were collected. Progress was 
defined by confirmed imaging or clinical examination.
Preparation of Snap-Frozen Samples of OC
Tissue specimens were collected immediately after the removal 
of the tumors, and samples were immediately snap-frozen and 
stored in liquid nitrogen. Histopathological evaluation of tumor 
samples was performed by an independent pathologist at the Insti-
tute of Pathology, Charité Medical University, Berlin, Germany. 
Histopathological evaluation was carried out on hematoxylin and 
eosin (H&E) stained 2–3 mm thick cryosections. Tumor origin, his-
tological type of tumor, and tumor grading according to the Silver-
berg grading system of epithelial ovarian tumors were evaluated.
Western Blot Analysis
Fifty milligram of OC tissue (n = 106) in 200 µL TPER buffer 
(Thermo Fisher Scientific, Bonn, Germany) was lyzed (Precyl-
lis-24 homogenizer; Peqlab, Erlangen, Germany), 50 µg of total 
protein were separated by SDS-PAGE (10% polyacrylamide gel; 
Bio-rad) and blotted onto a Immobilon-FL Transfer Membrane 
(MerckMillipore, Darmstadt, Germany). Target proteins were de-
tected by antibodies directed against PAI-1 (Cell Signaling Tech-
nology, Danvers, MA, USA; 1: 1,000), PAI-RBP1 (Sigma-Aldrich; 
1: 1,000), and β-actin (Cell Signaling Technology; 1: 1,000) as load-
ing control in combination with fluorescent dye-labeled antibod-
ies goat-anti-rabbit 680 (LI-COR Biotechnology, Bad Homburg, 
Germany; 1: 10,000) and goat-anti-rabbit 800 (LI-COR Biotech-
nology; 1: 10,000). Proteins were visualized using the Odyssey Im-
ager (LI-COR Biotechnology) and quantified applying the Image 
Studio Lite V4.0 software (LI-COR Biotechnology). PAI-1 and 
PAI-RBP1 expression was normalized to β-Actin and signal inten-
sity was expressed in densitometric arbitrary units (AU).
Preparation of Primary OC Cells
OC tissue samples (5–10 mm3) from 24 patients were main-
tained in PBS (Biochrom, Berlin, Germany) supplemented with 
50 µg/mL gentamicin (Ratiopharm, Ulm, Germany), digested with 
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collagenase I (Biochrom) for 1 h, and filtrated through a 40-μm 
nylon sieve (BD Falcon, Heidelberg, Germany). Separated cells 
were propagated in DMEM/F-12 supplemented with 10% fetal bo-
vine serum (Invitrogen, Karlsruhe, Germany) and 50 µg/mL gen-
tamicin (Ratiopharm). Primary ovarian cells from nonmalignant 
women undergoing a hysterectomy were used as control cells.
Indirect Immunofluorescence Microscopy Analysis
Primary OC cells were grown in 8-chamber LAB-TEK slides 
(NalgeNunc International, Naperville, USA), fixed with 3.7% PFA, 
and stained with Hoechst 33258 dye (5 µg/mL). Subsequently, cells 
were incubated with antibodies against PAI-1 (Santa Cruz; 1: 75) 
and PAI-RBP1 (Sigma-Aldrich; 1: 100) followed by staining with 
Alexa Fluor 488- and Alexa Fluor 546-conjugated antibodies, re-
spectively (each Invitrogen, Karlsruhe, Germany; 1: 200). Expres-
sion of mesothelin (Abcam, Frankfurt; Germany; 1: 100) and vi-
mentin (Santa Cruz; 1: 100) was used as OC-specific marker. Indi-
rect immunofluorescence analysis was performed using an Axio 
Observer Z1 fluorescence microscope with Axio Vision 4.8 soft-
ware (Zeiss, Jena, Germany).
Statistical Analysis
Statistical analysis was performed using SPSS statistical soft-
ware package (SPSS Inc. Version 19.0, Chicago, IL, USA). For cat-
egorical variables, chi-square, and 2-sided Fisher’s exact test were 
used in order to detect differences between groups, a parametric 
2-tailed test for comparisons between mean values and a nonpara-
metric Kruskal-Wallis test for group differences in non-normal or 
ordinal data. Pearson’s correlations were calculated to assess as-
sociations between continuous variables. The Cox proportional 
hazards regression model was used for univariate and multivariate 
analyses. p values and 95% CIs were calculated. p values <0.05 were 
considered statistically significant. Survival analyses were carried 
out by the Kaplan-Meier test with log rank test for determining the 
comparison of differences in survival curves.
Results
Details of the main clinicopathological characteristics of 
the patients are shown in Table 1. The median age at first 
diagnosis of OC was 57 years (range 22–85 years). The ma-
jority of patients were diagnosed when they were in an ad-
vanced tumor stage (FIGO III and IV; 83.3%), formed as-
cites (85.2%), and exhibited peritoneal carcinomatosis 
(77.6%). Sufficient tumor resections (tumor residual ≤1 
cm) were achieved in 79.1% (primary OC) and 54.1% (re-
current OC) of patients. In total, 66.7% of recurrent OC 
patients received a salvage surgery and serous type was the 
predominant histological OC subtype (80.1%). Further-
more, 91.6% of all tumors demonstrated intermediate 
(28.8%) and poorly (62.8%) differentiated tumor grading. 
The median progression-free survival (95% CI) and overall 
survival (95% CI) were 14 months (range 11.6–16.4 months) 
and 37 months (range 29.7–44.3 months), respectively.
Endogenously expressed PAI-1 and PAI-RBP1 pro-
tein demonstrated the calculated protein weight of ap-
proximately 50 and 53 kDa, respectively (Fig.  1). The 
mean relative densitometric intensity of both proteins 
was 0.161 ± 0.198 AU (PAI-1) and 0.361 ± 0.303 AU 
(PAI-RBP1), respectively. Comparison of primary and re-
current OC samples demonstrated no significant differ-
ences in PAI-1 expression (0.156 ± 0.200 AU vs. 0.167 ± 
0.195 AU; Fig. 2a), however, the expression of PAI-RBP1 
was significantly higher in primary OC compared to re-
current OC tissue (0.432 ± 0.265 AU vs. 0.291 ± 0.324 AU; 
p = 0.005; Fig. 2b).
Data from fluorescence microscopy performing triple 
staining for PAI-1 (green), PAI-RBP1 (red), and Hoechst 
staining of nuclei (blue; Fig. 3) of primary OC cells showed 
PAI-1 protein being diffusely localized throughout the 
nuclei and the perinuclear area of cells obtained from pri-
mary OC tissue. Notably, cells prepared from recurrent 
OC tissue exhibited PAI-1 exclusively localized in the nu-
cleus and, therefore, suggesting a PAI-1 translocation 
from the perinuclear compartment to the nucleus. In case 
of PAI-RBP1, the protein was found to be exclusively dis-
tributed in the cytoplasm of both primary as well as recur-
rent OC tissue cells.
Correlation analysis demonstrated a statistically sig-
nificant association between the densitometric intensity 
of PAI-1 and volume of ascites (p = 0.011), FIGO tumor 
stage (p = 0.028), lymphnode status (p = 0.002), and pM 
(p = 0.016). In case of PAI-RBP1 analysis, a statistically 
significant correlation between PAI-RBP1 and diagnosis 
(primary OC vs. recurrent OC, p < 0.001), age at first di-
agnosis (p = 0.025), histological tumor type (p = 0.026), 
and pM (p = 0.020) was found.
In univariate analysis, PAI-1 expression showed a 
trend toward association with progression-free surviv-
al  (p = 0.065), but it showed no correlation to overall 
 survival (p = 0.636). PAI-RBP1 was found to have a sta-
tistically significant association with progression-free 
survival (p = 0.047) and no correlation to overall survival 
(p = 0.709).
Cox proportional hazard ratios (HR) adjusted for age, 
tumor stage, histological type, and response to platinum 
therapy were calculated for PAI-1 and PAI-RBP1. 
 PAI-1  was not found to be an independent predictor 
for progression-free survival (HR 0.34, 95% CI 0.01–7.89; 
p = 0.50) and overall survival (HR 1.66, 95% CI 0.39–7.14; 
p = 0.49). The HR for progression-free survival remained 
not significant for PAI-RBP1 with a HR of 0.53 (95% CI 
0.18–1.50; p = 0.23), however, PAI-RBP1 turned out to be 
an independent prognostic factor for overall survival (HR 
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0.27, 95% CI 0.10–0.72; p = 0.009). Besides the correlation 
of PAI-1/PAI-RBP1 and clinicopathological parame-
ters  in OC patients, progression-free survival within 
the cohort was strongly correlated to tumor residual mass 
(p = 0.001), FIGO tumor stage (p < 0.001), pT (p = 0.001), 
pN (p = 0.002), pM (p = 0.010), grading (p = 0.002), and 
response to chemotherapy (p < 0.001).
Additionally, a significant association with overall sur-
vival was found for age (p = 0.013), peritoneal carcinoma-
tosis (p = 0.007), volume of ascites (p = 0.024), tumor re-
Table 1. Clinicopathological characteristics of OC patients
Clinicopathological characteristics
total primary OC recurrent OC
Number of patients, n 156 84 72
Age at first diagnosis, years, median (range) 57 (22–85) 61 (22–85) 54 (26–75)
Tumor
FIGO tumor stage, n (%)
I 10 (6.4) 8 (9.5) 2 (2.8)
II 9 (5.8) 6 (7.1) 3 (4.2)
III 108 (69.2) 47 (56) 61 (84.7)
IV 22 (14.1) 16 (19) 6 (8.3)
na 7 (4.5) 7 (8.3) 0
Volume of ascites, n (%)
No 6 (3.8) 3 (3.6) 3 (4.2)
≤500 mL 66 (42.3) 28 (33.3) 38 (52.8)
>500 mL 67 (42.9) 36 (42.9) 31 (43.1)
na 17 (10.9) 17 (20.2) 0
Peritoneal carcinomatosis, n (%)
No 16 (10.3) 10 (11.9) 6 (8.3)
Yes 121 (77.6) 56 (66.7) 65 (90.3)
na 19 (12.2) 18 (21.4) 1 (1.4)
Tumor residual, n (%)
No 48 (30.8) 31 (36.9) 17 (23.6)
≤1 cm 38 (24.3) 22 (26.2) 16 (22.2)
≤2 cm 6 (3.8) 0 6 (3.8)
>2 cm 47 (30.1) 14 (16.7) 33 (45.9)
na 17 (10.9) 17 (20.2) 0
Histo-pathology
Histological subtype, n (%)
Serous 125 (80.1) 59 (70.2) 66 (91.7)
Mucinous 4 (2.6) 3 (3.6) 1 (1.4)
Endometrioid 8 (5.1) 6 (7.1) 2 (2.8)
Clear cell 1 (0.6) 0 1 (1.4)
Mixed 6 (3.8) 6 (7.1) 0
Undifferentiated 7 (4.5) 6 (7.1) 1 (1.4)
na 5 (3.2) 4 (4.8) 1 (1.4)
Grading, n (%)
G1 3 (1.9) 3 (3.6) 0
G2 45 (28.8) 24 (28.6) 21 (29.2)
G3 98 (62.8) 48 (57.1) 21 (29.2)
na 10 (6.4) 9 (10.7) 1 (1.4)
Follow-up
Response to chemotherapy, n (%)
Non-responder 34 (21.8) 14 (16.7) 20 (27.8)
Responder 82 (52.6) 41 (48.8) 41 (56.9)
No chemotherapy 15 (9.6) 8 (9.5) 7 (9.7)
na 25 (16.0) 21 (25) 4 (5.6)
Survival, years, median (95% CI)
PFS 14 (11.6–16.4) 18 (13.3–22.7) 12 (8.5–15.5)
OS 37 (29.7–44.3) 27.5 (13.9–41.1) 45 (32–58)
na, not available.
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sidual mass (p ≤ 0.001), FIGO tumor stage (p = 
0.008), pT (p = 0.001), pN (p = 0.005), pM (p < 0.001), 
grading (p = 0.019), histological type (p = 0.036), and re-
sponse to chemotherapy (p < 0.001). In multivariate anal-
ysis, various clinical factors were found to be independent 
prognostic factors for progression-free survival (tumor 
residual, HR 2.29, 95% CI 1.01–5.19; p = 0.047) and over-
all survival (age, HR 2.12, 95% CI 1.31–3.44; p = 0.002; pT, 
HR 4.89, 95% CI 1.34–17.89; p = 0.016; pM, HR 5.34, 95% 
CI 2.09–13.66; p < 0.001; histological type, HR 4.59, 95% 
CI 2.07–10.19; p < 0.001 and platinum sensitivity, HR 
2.56, 95% CI 1.45–4.51; p = 0.001).
Discussion
Originally, PAI-RBP1 has been characterized as a 
 PAI-1 mRNA binding factor that potentially controls or 
contributes to PAI-1 mRNA turn-over [9]. Lemos and 
Kobarg [11] examined the localization of PAI-RBP1 in 
cervical HeLa cells and observed PAI-RBP1-GFP expres-
sion in the cytoplasm as well as in the nucleus. This is in 
contrast to our own findings reported here, in which 
 PAI-RBP1 has been expressed exclusively in the cyto-
plasm of primary and relapsed OC tissue samples. How-
ever, this may depict differential PAI-RBP1 functions de-
pending on the cellular context in cervix and ovary tissue. 
Notwithstanding, the putative properties of PAI-RBP1 in 
mature mRNA turn-over [12, 13] do not strictly require 
the protein’s presence in the nucleus.
In contrast to PAI-RBP1, there is less information 
available about PAI-1’s functionality in physiology as well 
as in pathology of mammalian cells. Notably, we found 
intense signals for PAI-1 in the nucleus of primary OC 
cells originated from relapsed OC patient samples. This 
is in line with previous reports of nuclear PAI-1 localiza-
tion [14, 15], however, to the best of our knowledge, there 
are no studies in which the nuclear import of PAI-1 has 
Fig. 1. PAI-1 (a) and PAI-RBP1 (b) expres-
sion in OC patient samples.
Fig. 2. Densitometric quantification of Western blot analysis. PAI-1 (a) and PAI-RBP1 (b) signals from primary and 
recurrent OC patient are shown as mean ± SD of signal intensity.
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been induced during cancer development. In this respect, 
the possibility that a so far unknown nuclear activity of 
PAI-1 is induced during OC recurrence cannot be ex-
cluded. Thus, the activation of PAI-1’s nuclear import 
may serve as a new prognostic biomarker for OC recur-
rence.
Apart from molecular and cellular aspects, our study 
revealed a statistically significant impact of PAI-1 and 
PAI-RBP1 protein expression on OC patient’s clinical 
prognosis. While former studies on PAI-1 expression in 
OC demonstrated controversial data regarding its clinical 
relevance [16–18], however, our study significantly cor-
related PAI-1’s expression levels with a more aggressive 
OC phenotype (volume of ascites, FIGO staging, lymph 
node status) and thus highlighting PAI-1’s prognostic 
value. These findings are similar to those found in a re-
Fig. 3. Fluorescence microscopy (magnification ×60) and analysis of Hoechst staining (a, b), PAI-1 (c, d), and 
PAI-RBP1 (e, f) in primary cells obtained from primary (a, c, e) and recurrent (b, d, f) OC patients.
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cent study of Ren et al. [19], which showed PAI-1 being 
correlated to advanced FIGO stage, poor histological dif-
ferentiation, and lymph node metastasis. Even though 
PAI-1 demonstrated a trend toward progression-free sur-
vival (p = 0.065) but no correlation with overall survival, 
PAI-1 may serve as a suitable prognostic biomarker for 
OC.
PAI-RBP1 expression significantly correlates with OC 
diagnosis (age at first diagnosis, histological tumor type, 
presence of distant metastasis, recurrence) and, moreover, 
PAI-RBP1 might be an independent predictor for overall 
survival (HR 0.27, p = 0.009). These data confirmed our 
initial study [8] and demonstrated for the first time a prog-
nostic value of PAI-RBP1 in OC. Our data, taken together 
with recent studies, demonstrated for the first time at the 
level of protein expression that PAI-RBP1 may represent 
a prognostic biomarker for OC, particularly in advanced 
metastatic stages. The most important limitation of the 
study presented here is its low number of included pa-
tients. Reevaluation of the dual-biomarker PAI-1/PAI-
RBP1 within a larger cohorte would be desirable. A further 
limitation of the study is the short follow-up of patients as 
well as the not randomized, single-arm design of the study.
In conclusion, we have shown that PAI-1 and 
 PAI-RBP1 may play a mechanistic role in OC progres-
sion and that expression levels of both proteins are asso-
ciated with patient outcome. A combination of both fac-
tors, PAI-1 as well as PAI-RBP1, may represent a novel 
prognostic factor in OC including progression-free sur-
vival and overall survival. Moreover, PAI-1’s nuclear im-
port may serve as an innovative prognostic biomarker for 
OC recurrence.
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